James Breen Journalist Profile

Articles

Christian Medical Witness to a Secular Culture

Sep 27, 2024 | crisismagazine.com | James Breen

For Catholic medical professionals, the annual conference of the Catholic Medical Association provides much needed educational and spiritual sustenance. This year’s event, which was recently held in Orlando, was no exception. On my drive home, I reflected on the blessing of this much-anticipated autumnal event, which offers Catholic medical professionals an energizing blend of medical education and spiritual retreat, fraternity and fellowship.
Dis-Organized Medicine, by James O. Breen, M.D.

Apr 10, 2024 | brownpelicanla.com | James Breen

In the interest of introducing an alternative viewpoint to their readerships, I submitted the following article to a string of general medical journals, including those representing my specialty. Seeing as all have foreclosed this opportunity to engage in a discussion that is truly inclusive of other viewpoints, I make it available to you, dear reader of Crisis.
Dis-Organized Medicine

Apr 10, 2024 | crisismagazine.com | James Breen

Many physicians share my dismay at the militancy of our professional associations’ alliance with an anti-human ideology. Mainstream medical journals continue to promote anti-scientific, anti-Hippocratic ideas without a shred of nuance and without allowing for dissent or debate among colleagues or constituents. Transgenderism, unfettered abortion license, and racial preferentialism are now the abiding values of our current medical elites.
Si G.K. Chesterton fuera hoy médico

Dec 10, 2023 | tradicionviva.es | James Breen

Por James O. Breen, M.D.Recientemente, me encontré con un artículo en Becker’s Hospital Review que celebraba la nueva generación de “funcionarios de diversidad, equidad e inclusión” en los sistemas de salud de todo el país. Entre otras tareas vitales para la salud de la nación, estos nuevos habitantes de la alta dirección están “instituyendo sesiones de capacitación” y “mejorando las prácticas de contratación” para “elevar a las poblaciones diversas” y “mejorar la equidad en la salud”.
If G.K. Chesterton Were a Doctor Today

Dec 6, 2023 | lewrockwell.com | James Breen

article-single If G.K. Chesterton Were a Doctor Today By James O. Breen, M.D. Crisis Magazine Recently, I came across an article in Becker’s Hospital Review celebrating the newest crop of “Diversity, Equity and Inclusion officers” in health systems across the country.
If G.K. Chesterton Were a Doctor Today

Dec 5, 2023 | crisismagazine.com | James Breen

Recently, I came across an article in Becker’s Hospital Review celebrating the newest crop of “Diversity, Equity and Inclusion officers” in health systems across the country.
BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Status

Nov 16, 2023 | mondaq.com | James Breen

Recently, Biogen and Samsung Bioepis's ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration. BYOOVIZ was deemed interchangeable to Genentech's LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. BYOOVIZ, the first FDA approved ophthalmology biosimilar, was launched in the United States in July 2022.
BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Status | JD Supra

Nov 13, 2023 | jdsupra.com | James Breen

Recently, Biogen and Samsung Bioepis’s ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration. BYOOVIZ was deemed interchangeable to Genentech’s LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. BYOOVIZ, the first FDA approved ophthalmology biosimilar, was launched in the United States in July 2022.
BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Status

Nov 11, 2023 | lexblog.com | James Breen

Recently, Biogen and Samsung Bioepis’s ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration. BYOOVIZ was deemed interchangeable to Genentech’s LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. BYOOVIZ, the first FDA approved ophthalmology biosimilar, was launched in the United States in July 2022.
BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Status

Nov 10, 2023 | bigmoleculewatch.com | Samsung Bioepis |James Breen

Recently, Biogen and Samsung Bioepis’s ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration. BYOOVIZ was deemed interchangeable to Genentech’s LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. BYOOVIZ, the first FDA approved ophthalmology biosimilar, was launched in the United States in July 2022.